<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742533</url>
  </required_header>
  <id_info>
    <org_study_id>BKCR-POF-1(Ⅰ)</org_study_id>
    <nct_id>NCT01742533</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure</brief_title>
  <official_title>A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Beike Bio-Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Beike Bio-Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum
      gonadotrophins and hypoestrogenism levels in female before the age of 40. It has important
      physical and psychological consequences/impact in those patients.

      Premature ovarian failure (POF) is currently managed by non-physiological sex steroid
      regimens which are inadequate at optimizing uterine characteristics.

      Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells
      (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance
      angiogenesis, suggesting the novel and promising therapeutic strategy for POF.

      In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation combined with
      Hormone Replacement Therapy will be evaluated in patients with Premature Ovarian Failure.
      Participants will be followed for an expected average of 48 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Level of follicle-stimulating hormone</measure>
    <time_frame>48 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine and Ovary characteristics of B ultrasound， including Uterine/Ovarian size and Blood Flow</measure>
    <time_frame>48 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Kupperman Score</measure>
    <time_frame>48 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events</measure>
    <time_frame>48 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Premature Ovarian Failure，</condition>
  <arm_group>
    <arm_group_label>Group1 : HRT plus hUCMSCs treatment:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: HRT plus hCBMNCs and hUCMSCs therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3 : HRT plus hCBMNCs treatment:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4:Hormone Replacement Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <arm_group_label>Group1 : HRT plus hUCMSCs treatment:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hUCMSCs and hCBMNCs</intervention_name>
    <arm_group_label>Group 2: HRT plus hCBMNCs and hUCMSCs therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human cord blood mononuclear cells</intervention_name>
    <arm_group_label>Group3 : HRT plus hCBMNCs treatment:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone Replacement Therapy</intervention_name>
    <arm_group_label>Group 4:Hormone Replacement Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between age 18- 39 years, Female only.

          -  Diagnosed with Premature Ovarian Failure，and currently receiving Hormone Replacement
             Therapy;

          -  Willing to sign the Informed Consent Form.

        Exclusion Criteria:

          -  Fragile X chromosome.

          -  polycystic ovary syndrome.

          -  HIV+.

          -  Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.

          -  Severe pulmonary and hematological disease, malignancy or hypo-immunity.

          -  Currently undertaking other treatment that may affect the safety/efficacy of stem
             cells.

          -  Pregnancy or lactation

          -  Enrollment in other trials in the last 3 months. • Other criteria the investigator
             consider improper for inclusion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FangMing Su, Master</last_name>
    <phone>86-755-25533018</phone>
    <email>sfmlxq@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fangming Su</last_name>
      <phone>86-755-25533018</phone>
      <email>sfmlxq@163.com</email>
    </contact>
    <investigator>
      <last_name>Fangming Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>December 2, 2012</last_update_submitted>
  <last_update_submitted_qc>December 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone Replacement Therapy，</keyword>
  <keyword>Premature Ovarian Failure，</keyword>
  <keyword>Stem Cell Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

